Resources

Presentations

January 5, 2022

Corporate Presentation - January 2022

November 11, 2021

Research and Development Day Presentation - November 2021

Milademetan Posters & Presentations

AACR-NCI-EORTC 2021

Vijaya G. Tirunagaru, PH.D.

MDM2gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan

AACR-NCI-EORTC 2021

Vijaya Tirunagaru, Ph.D.

The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer

AACR-NCI-EORTC 2021

Varsha Ananthapadmanabhan, Ph.D.

Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines

IASLC 2021 World Conference on Lung Cancer

Lynn Heasley, Ph.D.

The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma

EORTC-NCI-AACR 2020

Mrinal M. Gounder

Milademetan (DS-3032b or RAIN-32), an Oral MDM2 Inhibitor, in Well-Differentiated/Dedifferentiated Liposarcoma: Results From a Phase 1 Study in Patients With Solid Tumors or Lymphomas

ASH 2019

Courtney D. DiNardo

A Phase 1 Dose-Escalation Study of Milademetan in Combination With 5-Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

ASH 2019

A Phase 1 Study of Milademetan in Combination With Quizartinib in Patients With Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)

ESMO 2019

A Phase 2 biomarker-driven study evaluating the clinical efficacy of MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need

Rad52 posters & presentations

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors

Nucleic Acids Res. 2016 May 19;44(9):4189-99

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells

Cell Rep. 2018 Jun 12;23(11):3127-3136.